The talking mycobacterium abscessus blues

Clinical Infectious Diseases

Volumn 52, Issue 5, 2011, Pages 572-574

  Griffith, David E ^a  

^a UNIVERSITY OF TEXAS AT TYLER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZITHROMYCIN; CEFOXITIN; CIPROFLOXACIN; CLARITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; MACROLIDE; SULFONAMIDE; TIGECYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; DRUG EFFICACY; HUMAN; LUNG DISEASE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM ABSCESSUS; NONHUMAN; PRIORITY JOURNAL; RELAPSE; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOSIS;

ANTI-BACTERIAL AGENTS; CHRONIC DISEASE; DEBRIDEMENT; HUMANS; MYCOBACTERIUM; MYCOBACTERIUM INFECTIONS; PNEUMONIA, BACTERIAL; TREATMENT OUTCOME;

EID: 79951824945     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciq252     Document Type: Review

References (10)

1. Griffith DE, Girard WM, Wallace RJ Jr. Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients. Am RevRespir Dis 1993;147:1271-8. (Pubitemid 23149890)
2. Jarand JM, Levin A, Zhang L, Huitt G, Mitchell JD, Daley CL. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis 2010;52:564-571.
3. Jeon K, Kwon OJ, Lee NY, Kim BJ, Kook YH, et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med 2009;180:896-902.
4. Nash KA, Brown-Elliott BA, Wallace RJ Jr. A novel gene, erm (41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 2009;53:1367-76.
5. Koh WJ, Jeon K, Lee NY, Kim BJ, Kook YH, et al. Clinical significance of differentiation of ycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med 2010. [epub ahead of print].
6. Leao SC, Tortoli E, Euzéby JP, Garcia MJ. Proposal that the two species Mycobacterium massiliense Mycobacterium bolletii be reclassified as Mycobacterium abscessus subsp. bolletii comb. nov., designation of Mycobacterium abscessus subsp. abscessus subsp. nov., and emendation of Mycobacterium abscessus. Int J Syst Evol Microbiol 2010. [epub ahead of print].
7. Wallace RJ, Brown-Elliott BA, Ward SC, Crist CJ, Mann LB, Wilson RW. Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother 2001;45:764-7. (Pubitemid 32182022)
8. Wallace RJ, Brown-Elliott BA, Crist CJ, Mann L, Wilson RW. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and docycycline against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother 2002;46:3164-7.
9. Griffith DE, Aksamit T, Brown-Elliott BA, et al. Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367-416.
10. Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005;307:223-7. (Pubitemid 40116230)